Home » Health » Diseases & Condition » Resources for Providers » Carbapenem-resistant Enterobacteriaceae CRE

Carbapenem-resistant Enterobacteriaceae (CRE)


CRE, defined as Enterobacteriaceae (Klebsiella sp., E. coli, and Enterobacter sp.) resistant to carbapenem antibiotics or that produce carbapenemases, are epidemiologically important healthcare-associated pathogens. Studies have shown that CRE infections are difficult to treat, as some have become resistant to all or almost all antibiotics. The mortality rate is high, and infection is easily spread between patients in healthcare facilities. Clinicians play a critical role in slowing the spread of CRE by rapidly identifying patients colonized or infected with these organisms and placing them on Contact Precautions when appropriate, using antibiotics wisely, and minimizing device use.    

On January 19, 2017, the Long Beach City Health Officer issued an Order requiring all acute care hospitals and skilled nursing facilities to report cases of CRE. In addition, acute care hospitals and skilled nursing facilities that generate antibiograms are required to submit them once a year to Public Health. For more information, please contact the Emerging Infectious Disease Response Coordinator at 562.570.4344.


CRE Clinician FAQ

CRE FAQ for Patients Eng

CRE Reporting FAQ LB

News Release January 19, 2017County of Los Angeles Public Health - Drug-Resistant CRE Added to List of Reportable Diseases

News Release January 31, 2017: County of Los Angeles Public Health - Drug Resistant E. coli Bacteria Identified in LA County Resident

CRE Health Officer Order

CRE Facility Notification

For more information on CRE, visit the CDC website for clinicians:


CRE Toolkit: https://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html